Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

Executive Summary

Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.

You may also be interested in...



Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer

Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.

Coronavirus Update: Alexion Tests Ultomiris in ARDS

More Phase III trials announced from Alexion and Novartis, while Karyopharm investigates potential of repurposed cancer therapy.

FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology

The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel